****

**IND Amendment: New Protocol**

This Submission Should Include:

* Cover Letter
* Form 1571
* Form 3674
* Table of Contents
* New Protocol
* Investigator Brochure if changed or new one
* Informed Consent Form

This document should be paginated.

If you are adding new investigators, include information from that template / documents.

Note: If the IND is already in effect (i.e. it has either received approval or has waited the 30 days), the amendment to protocol submissions do not require a waiting period. You can submit to both IRB and FDA at the same time. If you are waiting for an FDA opinion regarding the protocol, then you should wait 30 days before asking about the review. Do not start the study until these questions are answered and FDA agrees with starting.

Submit to CRCO via REDCap Survey at go.vcu.edu/indide

Revision History

Version1: June 6, 2014

Version2: October 9, 2017

**

*Investigator-Sponsor’s Name*

*Academic Department of Investigator-Sponsor*

XXaddressXX

Richmond, VA 23298

*Check your letter from the FDA regarding address and contact.*

*Address for Drug Products regulated by CDER (incorporate if applicable):*

*Food and Drug Administration*

*Center for Drug Evaluation and Research*

*Specify applicable CDER review division*

*Central Document Room*

*5901-B Ammendale Road*

*Beltsville, MD 20705-1266*

*Address for Biological Products regulated by CDER (incorporate if applicable):*

*Food and Drug Administration*

*Center for Drug Evaluation and Research*

*Specify applicable CDER review division*

*Therapeutic Biological Products Document Room*

*5901-B Ammendale Road*

*Beltsville, MD 20705-1266*

*Address for Biological Products regulated by CBER (incorporate if applicable):*

*Food and Drug Administration*

*Center for Biologics Evaluation and Research*

*Document Control Center*

*10903 New Hampshire Avenue*

*Building 71, Room G112*

*Silver Spring, MD 20993-0002*

Date:

Re: **IND Protocol Amendment:** *Specify type of amendment (i.e.* ***N*ew Protocol**; **Change in Protocol**; or **New Investigator**)

**IND #** *Specify IND number*

To Whom It May Concern:

Per 21 CFR § 312.30 (a), enclosed please find a new protocol enclosed entitled (ener new protocol number and name). investigator information for (insert protocol name(s) and number). Three copies (the original and 2 photocopies) are included.

**Significant Differences between New and Previously Submitted Protocol(s)**

*Provide a brief description of the most clinically significant differences between the new protocol (which must be provided to the FDA as part of this submission) and previously submitted protocols*

*Provide a reference, if necessary, to specific technical information in the IND or in a concurrently submitted Information Amendment to the IND that the investigator-sponsor relies on to support any clinically significant change(s) in the new protocol. If the reference is made to supporting information already in the IND, the investigator-sponsor shall identify by name, reference number, volume, and page number the location of the information*

**Request for Comments** *(Include this section, as applicable)*

*If desired, state your request for the FDA’s comments on the new protocol submission, including any specific questions you would like the FDA to address.*

Please let me know if you have questions or concerns about the enclosed submission. I can be reached at (insert contact information)

Sincerely,

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Signature of Investigator-Sponsor Printed Name of Investigator-Sponsor